Last reviewed 2026-04-23 · How we verify

AK104 lenvatinib

AK104 lenvatinib is a tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors (VEGFR) and fibroblast growth factor receptors (FGFR).

AK104 lenvatinib is a tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors (VEGFR) and fibroblast growth factor receptors (FGFR). Used for Metastatic renal cell carcinoma, Papillary thyroid carcinoma.

At a glance

Mechanism of action

By inhibiting these receptors, AK104 lenvatinib reduces tumor angiogenesis and growth. This mechanism is similar to other lenvatinib-based treatments.

Approved indications

• Metastatic renal cell carcinoma
• Papillary thyroid carcinoma

Common side effects

• Hypertension
• Diarrhea
• Fatigue
• Nausea
• Weight loss

Key clinical trials

• Study of Cadonilimab (AK104) Plus Lenvatinib in Patients With Advanced Endometrial Cancer (PHASE2)
• Second-line Treatment With CAdonilimab and LEnvatinib for Unresectable HCC (PHASE2)
• A Phase II Study of AK104 Combination With Lenvatinib Versus Lenvatinib for Second-line HCC (PHASE2)
• A Phase II Study of AK104 Plus Lenvatinib and TACE in HCC (PHASE2)
• A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (PHASE3)
• A Study of Cadonilimab（AK104） Plus Lenvatinib in Previous Immunotherapy Treated Advanced/Metastatic Clear Cell Renal Cell Carcinoma (PHASE2)
• Cadonilimab in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment of Unresectable Hepatocellular Carcinoma (PHASE2)
• A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Alone or in Combination With Lenvatinib in Advanced Hepatocellular Carcinoma (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.